XML 13 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Income Statement [Abstract]    
Net Sales $ 424,462 $ 1,641,028
Cost of Sales 203,356 1,337,942
Gross Profit 221,106 303,086
Operating expenses    
Compensation and related expenses 358,488 240,455
Professional fees 99,632 69,315
Marketing expenses 10,800
General and administrative expenses 127,172 98,412
Total operating expenses 596,092 408,182
Operating (Loss) (374,986) (105,096)
Change in fair value of derivative liability (48,192)
Interest (expense) (649,357) (3,063)
Net (Loss) (1,072,535) (108,159)
Net (loss) attributable to noncontrolling interests (27,730) (46,110)
Net (loss) attributable to Immudyne, Inc. $ (1,044,805) $ (62,049)
Basic and diluted (loss) per share attributable to Immudyne, Inc. $ (0.03) $ 0.00
Average number of common shares outstanding    
Basic 37,581,987 32,010,375
Diluted 37,581,987 32,010,375